Andrea Necchi, Associate Professor at Università Vita-Salute San Raffaele, shared on Linkedin:
“I am happy to announce that our request for the inclusion of Trastuzumab Deruxtecan (TDXd) in the 648 AIFA Agenzia Italiana del farmaco regimen for HER2+ urothelial carcinomas already treated with standard therapies is officially active.
This possibility comes a few weeks after the approval of European Medicines Agency demonstrating that even in Italy access to innovative therapies can be timely in the interest of patients Associazione PaLiNUro, Ospedale San Raffaele, Università Vita-Salute San Raffaele.
Other articles featuring Andrea Necchi on OncoDaily.